You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Latvia Drug Patents


✉ Email this page to a colleague

« Back to Dashboard


Drug Patents in Latvia and US Equivalents

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
Patent Number Estimated Expiration Equivalent US Patent US Expiry Date Generic Name US Applicant US Tradename
5781 ⤷  Free Trial 5034394 2012-06-18 abacavir sulfate Viiv Hlthcare ZIAGEN
5781 ⤷  Free Trial 5089500 2009-12-26 abacavir sulfate Viiv Hlthcare ZIAGEN
5781 ⤷  Free Trial 5034394 2012-06-18 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
5730 ⤷  Free Trial 5047407 2010-05-17 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
5781 ⤷  Free Trial 5089500 2009-12-26 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
5730 ⤷  Free Trial 7119202 2009-08-08 abacavir sulfate; lamivudine Viiv Hlthcare EPZICOM
5724 ⤷  Free Trial 4724232 2005-09-17 abacavir sulfate; lamivudine; zidovudine Viiv Hlthcare TRIZIVIR
>Patent Number >Estimated Expiration >Equivalent US Patent >US Expiry Date >Generic Name >US Applicant >US Tradename

Patentability, Enforceability, and Scope of Claims for Biopharmaceutical Patents in Latvia

Overview of Patent Registration in Latvia

When considering patent protection for biopharmaceutical inventions in Latvia, it is crucial to understand the overall process and requirements for patent registration. The Latvian Patent Office is responsible for handling patent applications, and the process involves several key steps, including formal and substantive examinations[5].

Patentability Criteria

For a biopharmaceutical invention to be patentable in Latvia, it must meet specific criteria:

Novelty

The invention must be new and not publicly disclosed before the filing date, except for a 6-month novelty grace period if the disclosure occurs at an international exhibition or by third parties in bad faith[1].

Industrial Applicability

The invention must be capable of being used in an industry. This criterion is verified during the substantive examination phase[5].

Inventive Step

Although not explicitly examined by the Latvian Patent Office during the substantive examination, the inventive step is a critical aspect of patentability. Applicants must ensure their invention is not obvious to a person skilled in the art[5].

Formal Examination

The formal examination is the initial step after filing the patent application. The Latvian Patent Office checks if all required documents are submitted, including the applicant's and inventor's names, addresses, and citizenships, as well as the specification with claims, abstract, and drawings. A Power of Attorney and a certified copy of the priority document (if priority is claimed) must also be provided within specified timeframes[1].

Substantive Examination

During the substantive examination, the Patent Office verifies if the invention corresponds to the requirements of industrial application, unity of the invention, biotechnological invention requirements, claim formatting rules, sufficiency, and added matter. However, the examination does not include assessing novelty, inventive step, and industrial application in detail[5].

Scope of Claims

For biopharmaceutical patents, the scope of claims is critical. In Latvia, claims must be clear and concise, and they must relate to the invention described in the specification. Here are some key points:

Claim Formats

Claims can be formatted to cover the use of a product for a specific purpose, but they must adhere to specific rules. For example, claims related to the use of a known product for a new medical purpose can be accepted if they are properly formulated, such as "use of X for the treatment of Y"[3].

Second Medical Use Inventions

Latvian patent law, similar to other jurisdictions, allows for the patenting of new medical uses of known products. However, the claims must be carefully drafted to focus on the new use rather than the product itself[3].

Enforceability of Patents

Validity Term

Patents in Latvia are valid for 20 years from the filing date. For pharmaceutical and agrochemical patents, an additional 5-year extension can be obtained through a Supplementary Protection Certificate (SPC)[1].

Court Proceedings

Patents issued in Latvia can be appealed in court if there are disputes over their validity or infringement. Foreign applicants must be represented by a registered Latvian patent attorney in such proceedings[1].

Compliance with Competition Law

Biopharmaceutical companies operating in Latvia must also comply with competition law. Recent developments in the pharmaceutical sector highlight the importance of adhering to competition rules to avoid fines and mandatory obligations. For instance, agreements that restrict competition, such as those on compensatory drug markups, can lead to significant penalties[2].

Representation and Filing Requirements

Foreign applicants must be represented by a registered Latvian patent attorney when filing patent applications. The application must include all necessary documentation, such as the Power of Attorney, which can be provided within three months from the application filing date[1].

Publication and Registration

After a positive formal examination, the patent application is published within 18 months from the filing date or the first earlier priority date. Once the substantive examination is completed and the state fee is paid, the patent is registered in the State Patent Register, and a notification is published in the Official Gazette of the Patent Office[5].

Opposition and Appeals

Third parties can oppose the grant of a patent within nine months from the publication date, claiming that the invention lacks novelty. The opposition process involves a state fee and can lead to the revocation of the patent if the opposition is successful[5].

International and European Patent Considerations

While Latvia does not allow entry into the national phase of a PCT application, applicants can consider European patent options, including the new Unitary Patent system. The Unitary Patent provides uniform protection across EU member states, but it does not replace national or traditional European patents[4].

Key Takeaways

  • Patentability Criteria: Biopharmaceutical inventions must meet novelty, industrial applicability, and inventive step criteria, although the latter two are not detailedly examined by the Latvian Patent Office.
  • Scope of Claims: Claims must be clear and focused on the new use of a known product, if applicable.
  • Enforceability: Patents are valid for 20 years, with possible extensions for pharmaceutical and agrochemical patents.
  • Compliance: Adherence to competition law is crucial to avoid penalties.
  • Representation: Foreign applicants must be represented by a registered Latvian patent attorney.
  • Publication and Registration: Patents are published and registered after successful examinations and payment of fees.

FAQs

Q: What is the validity term of a patent in Latvia? A: The validity term of a patent in Latvia is 20 years from the filing date, with possible extensions for pharmaceutical and agrochemical patents.

Q: Can foreign applicants file patent applications in Latvia without representation? A: No, foreign applicants must be represented by a registered Latvian patent attorney.

Q: How long does the patent registration process in Latvia typically take? A: The process typically takes from 1.5 to 2 years.

Q: Can biopharmaceutical companies patent new medical uses of known products in Latvia? A: Yes, but the claims must be carefully drafted to focus on the new use.

Q: What is the role of the Latvian Patent Office in the patent examination process? A: The Latvian Patent Office performs formal and substantive examinations to ensure the patent application meets the necessary criteria.

Cited Sources

  1. MSP Corporate: "PATENT in Latvia | MSP | Patent Registration in Latvia"
  2. Cobalt Legal: "Catching Up: Recent Developments in Pharma Sector Competition Law Across the Baltics"
  3. Gorodissky & Partners: "Second medical use inventions – Russian and Eurasian patent legislation"
  4. IQVIA: "An Overview of Unitary Patent and Unified Patent Court"
  5. Lavvocato: "Patent registration in Latvia - Valters Gencs"

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.